• Home
  • Contact Us

Soin Neuroscience

Developing treatments for chronic diseases

Developing treatments for chronic diseases
  • Home
  • About Us
  • Research & Development
    • Peripheral Arterial Disease
    • Diabetic Neuropathy
    • Additional Programs
  • Publications
    • Journal Articles
    • PAD, Diabetes & CLI Articles
    • Nitrite Articles
    • News Stories
  • Press Releases
  • Related Links
  • Contact Us
Home / Press Releases / Peripheral artery disease pill from TheraVasc heading to phase 2a trials

Peripheral artery disease pill from TheraVasc heading to phase 2a trials

September 27, 2010 By Dr. Amol Soin

TheraVasc plans to begin enrolling patients this month in a phase 2a clinical trial of its pill designed to treat peripheral artery disease.

The clinical trial, which is expected to follow 50 diabetic PAD patients for 11 weeks, could lead to big things for Cleveland-based TheraVasc. CEO Tony Giordano hopes a successful trial will position the company for a development partnership with a big drugmaker or a venture round of between $10 million and $20 million.

“We’re really excited that it’s finally getting rolling,” Giordano said. “Now we just have to get these patients in as quickly as possible, and see if the drug does what we expect it to do.”

The company is reformulating a drug — sodium nitrite — for the treatment of PAD, a condition in which narrowed arteries reduce blood flow to the limbs. The condition often afflicts diabetics and can result in the amputation of patients’ feet.
Advertisement

Sodium nitrite is available in injectable form, but TheraVasc is working to commercialize the drug in pill form. A capsule or tablet would not only be more user friendly, it would allow for a sustained release that would help patients maintain adequate levels of the drug over time.

In addition to measuring the drug’s safety and tolerability, the phase 2a clinical trial’s design calls for assessments of patients’ vascular integrity, walking ability and quality of life improvements at the end of the trial period, Giordano said.

Cleveland Clinic likely will be the first of eight clinical sites that will go live, with patient enrollment and dosing expected to begin this month. The University of Pennsylvania is another of the trial sites. Others will start up throughout the coming months.

TheraVasc closed a $2.1 million series A round of investment last year. Investors included JumpStart. Portal Capital, North Coast Angel Fund, Ohio TechAngels and Dayton-based Physician Investment Group. The company also last year received a $500,000 grant last year from the Global Cardiovascular Innovation Center on Cleveland Clinic’s campus, Giordano said.

Filed Under: Press Releases, Latest News

Recent Releases

  • TheraVasc Awarded “Most Promising Life Science Technology Company” at Rice Alliance Life Science Venture Forum
  • Peripheral artery disease drug developer TheraVasc raises $1.8M
  • Peripheral artery disease pill from TheraVasc heading to phase 2a trials
  • Startup Stories: A Race for Better Healing Therapies
  • TheraVasc’s clinical trial of PAD drug shows safety in diabetic patients
  • TheraVasc Releases Phase I Trial Data Demonstrating Safety of Drug in Diabetic Patients

Contact Us

Amol Soin, MD, MBA
7076 Corporate Way
Dayton, OH 45458
drsoin@soinneuroscience.com


7076 Corporate Way
Dayton, OH 45458
drsoin@soinneuroscience.com

Research

  • Peripheral Arterial Disease
  • Diabetic Neuropathy
  • Additional Programs

Publications

  • Journal Articles
  • PAD, Diabetes & CLI Articles
  • Nitrite Articles
  • News Stories

Company

  • About Us
  • Press Releases
  • Related Links
  • Contact Us
Copyright © 2021 Soin Neuroscience. All Rights Reserved.

MENU
  • Home
  • About Us
  • Research & Development
    • Peripheral Arterial Disease
    • Diabetic Neuropathy
    • Additional Programs
  • Publications
    • Journal Articles
    • PAD, Diabetes & CLI Articles
    • Nitrite Articles
    • News Stories
  • Press Releases
  • Related Links
  • Contact Us